Vor Ort
Merkzettel Warenkorb
Produktbild: Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development
- 11%

Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development

Aus der Reihe Methods in Pharmacology and Toxicology
11% sparen

103,99 € UVP 117,69 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

29.10.2016

Abbildungen

XVIII, 57 illus., 37 illus. in color., schwarz-weiss Illustrationen, farbige Illustrationen

Herausgeber

Steven J. Potts + weitere

Verlag

Springer Us

Seitenzahl

375

Maße (L/B/H)

25,4/17,8/2 cm

Gewicht

832 g

Auflage

Softcover reprint of the original 1st ed. 2015

Sprache

Englisch

ISBN

978-1-4939-5420-9

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

29.10.2016

Abbildungen

XVIII, 57 illus., 37 illus. in color., schwarz-weiss Illustrationen, farbige Illustrationen

Herausgeber

Verlag

Springer Us

Seitenzahl

375

Maße (L/B/H)

25,4/17,8/2 cm

Gewicht

832 g

Auflage

Softcover reprint of the original 1st ed. 2015

Sprache

Englisch

ISBN

978-1-4939-5420-9

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: GPSR Kontakt

Ein neues Kapitel für Ihre Bücher

Ein neues Kapitel für Ihre Bücher

Schenken Sie Ihren alten Schätzen ein zweites Leben: Einfach Barcode scannen, Versandetikett ausdrucken, Bücher verschicken und Thalia Geschenkkarte erhalten.

Jetzt verkaufen
Jetzt verkaufen

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development

  • Part I: Current Perspectives on the Pathology Discipline in the Pharma Industry

     

    1. Histopathology: A Canvas and Landscape of Disease in Drug and Diagnostic Development

                Keith A. Wharton, Jr.

     

    2. A Field Guide to Homo morphologicus for Biomedical Scientists, Or How to Convey an Understanding of Pathology to Scientists in a Biopharma Enterprise

                Humphrey Gardner

     

    3. Outsourcing Tissue Histopathology Investigations in Support of Clinical Trials for Novel Therapeutics: Considerations and Perspectives

                Keith A. Wharton, Jr., Benjamin H. Lee, Pierre Moulin, Dale Mongeon, Rainer Hillenbrand, Arkady Gusev, Bin Ye, and Xiaoyu Jiang

     

    4. Histopathology in Mouse Models of Rheumatoid Arthritis

                Patrick Caplazi and Lauri Diehl

     

    Part II: Current Directions in Histopathology for Drug Development, Involving Tissue Image Analysis

     

    5. Markers Used for Visualization and Quantification of Blood Vessels and Lymphatic Vessels

                Mohamed E. Salama, David A. Eberhard, and Steven J. Potts

     

    6. Practical Approaches to Microvessel Analysis: Hotspots, Microvessel Density, and Vessel Proximity

                Steven J. Potts, David A. Eberhard, and Mohamed E. Salama

     

    7. Quantitative Histopathology and Alternative Approaches to Assessment of Fibrosis for Drug Development in Hepatitis C and Nonalcoholic Steatohepatitis

                Steven J. Potts and Johanna K. DiStefano

     

    8. Stereology and Computer-Based Image Analysis Quantifies Heterogeneity and Improves Reproducibility for Grading Reticulin in Myeloproliferative Neoplasms

                Mohamed E. Salama, Erik Hagendorn, Sherrie L. Perkins, Jeff Kutok, Etman A, Josef T. Prchal, and Steven J. Potts

     

    9. Image Analysis Tools for Quantification of Spinal Motor Neuron Subtype Identities

                Mirza Peljto and Hynek Wichterle

     

    10. Development of a Tissue Image Analysis Algorithm for Celiac Drug Development

                Erik Hagendorn, Christa Whitney-Miller, Aaron Huber, and Steven J. Potts

     

    11. Quantitative Histopathology for Evaluation of In Vivo Biocompatibility Associated with Biomedical Implants

                Robert B. Diller, Robert G. Audet, and Robert S. Kellar

     

    12. Quantitative Histomorphometry and Quantitative Polymerase Chain Reaction (PCR) as Assessment Tools for Product Development

                Robert G. Audet, Robert B. Diller, and Robert S. Kellar

     

    Part III: Current Directions in Histopathology for Drug Development, Involving Molecular Histopathology: In Situ Hybridization

     

    13. Measuring the Messenger: RNA Histology in Formalin Fixed Tissues

                Steven J. Potts, Mirza Peljto, Mahipal Suraneni, and Joseph S. Krueger

     

    14. Algorithm-Driven Image Analysis Solutions for RNA ISH Quantification in Human Clinical Tissues

                Mirza Peljto, Joseph S. Krueger, Nicholas D. Landis, G. David Young, Steven J. Potts, and Holger Lange

     

    15. Solid Tissue-Based DNA Analysis by FISH in Research and Molecular Diagnostics

                Marcus Otte

     

    Part III: Current Directions in Histopathology for Drug Development, Involving Molecular Histopathology: Sequencing and Genomics

     

    16. Preanalytic Considerations for Molecular Genomic Analyses of Tissue

                Maureen Cronin

     

    17. Next Generation Sequencing (NGS) in Anatomic Pathology Discovery and Practice

                Matthew J. McGinniss, David A. Eberhard, and Keith A. Wharton, Jr.

     

    Part IV: Current Directions in Histopathology for Drug Development, Involving Companion Diagnostics

     

    18. The Impact of Pre-Analytic Variables on Tissue Quality from Clinical Samples Collected in a Routine Clinical Setting: Implications for Diagnostic Evaluation, Drug Discovery, and Translational Research

                David G. Hicks

     

    19. Adapting HER2 Testing for a Different Organ: New Wine in Old Wineskins

                Michael D. Lunt and Christa L. Whitney-Miller

     

    20. Tissue-Based Companion Diagnostics:  Development of IHC Assays from an Industry Perspective

                Miu Chau and Jon Askaa

     

    21. Development of Tissue-Based Companion Diagnostics:  The Relationship Between the Pharmaceutical Company, Diagnostic Partner, and the Biomarker Laboratory

                Mark  Kockx, Stefanie de Schepper, and Christopher Ung

     

    22. Navigating Regulatory Approval for Tissue-Based Companion Diagnostics

                Joseph S. Krueger, Holger Lange, G. David Young, and Steven J. Potts

     

    23. Implementing a Multi-Analyte Immunohistochemistry Panel into a Drug Development Program

                Carla Heise, Pierre Brousset, Tommy Fu, David A. Eberhard, Graham W. Slack, Camille Laurent, and Randy D. Gascoyne

     

    24. Cutpoint Analysis and Related Statistical Methods in Digital Pathology and Companion Diagnostics

                Joshua C. Black, Mahipal V. Suraneni, and Steven J. Potts